Phase II Clinical Trial Data with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib (OSI-774) in Non–Small-Cell Lung Cancer
References (32)
- et al.
Epidermal growth factor-related peptides and their receptors in human malignancies
Crit Rev Oncol Hematol
(1995) - et al.
The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors
Cytokine Growth Factor Rev
(1996) - et al.
Targeting the epidermal growth factor for chemotherapy of carcinomas
Biochem Pharmacol
(1996) - et al.
The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials
Eur J Cancer
(1994) - et al.
The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer
Int J Oncol
(1994) Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers
Br Med Bull
(1991)- et al.
The epidermal growth factor receptor as a target for therapy in breast carcinoma
Breast Cancer Res Treat
(1994) - et al.
Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells
Anticancer Res
(1999) - et al.
The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival
Br J Cancer
(1993) Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression
Clin Cancer Res
(1997)
EGFR expression correlates poor prognosis in non-small cell lung cancer (NSCLC) patients interacting with p53 overexpression
Proc Am Assoc Cancer Res
(1997)
Characterization of epidermal growth factor receptor in primary human non-small cell lung cancer
Cancer Res
(1989)
Role of epidermal growth factor receptor overexpression, K-ras point mutation and c-myc amplification in the carcinogenesis of non-small cell lung cancer
Oncol Rep
(1998)
Aberant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development
Cancer Res
(1995)
Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: and immunohistochemical study on cryosections
Br J Cancer
(1996)
Expression of epidermal growth factor receptor (EGF-R) in human lung tumours
Br J Cancer
(1986)
Cited by (0)
Dr. Perez-Soler receives grant and/or research support from OSI Pharmaceuticals and the National Institutes of Health; is a paid consultant for Genentech, OSI Pharmaceuticals, Amgen, Novartis, Eli Lilly, Transave, ALZA, and AstraZeneca; and is a stockholder of Genentech, OSI Pharmaceuticals, Amgen, Novartis, Eli Lilly, Transave, and AstraZeneca. He also receives other financial or material support from OSI Pharmaceuticals, Genentech, Amgen, Novarits, Eli Lilly, Bristol-Myers Squibb, Transave, and AstraZeneca.
This article includes discussion of unlabeled use of erlotinib or gefitinib in early-stage, chemotherapy-naive non–small cell lung cancer.
Copyright © 2004 Elsevier Inc. All rights reserved.